drugset / Trial / NCT03168711

Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)

NCT03168711

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multi-center, 20-week study of inosine treatment. Study Objectives and Endpoints The primary objective of the study is to determine the safety and tolerability of oral administration of inosine (administered daily) dosed to moderately elevate serum urate over 20 weeks. The primary outcome measures will be 1. Safety, as measured by adverse events 2. Tolerability, defined as the ability of subjects to complete the entire 20-week study. As an exploratory objective, we will test the feasibility and utility of a smartphone application for monitoring symptoms and disease progression in patients with amyotrophic lateral sclerosis (ALS).

Timeline

Start
2017-10-01
Primary completion
2019-12-10
Completion
2020-01-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Inosine Unknown 500 mg Oral